Taiwan FDA registration b211fd5c8be441579b909748183795a4
Qizhe cardiomyogen in vitro reagent group
TW: 啟哲心肌素體外試劑組
Taiwan·Risk Class 2·Longteng Biotechnology Co., Ltd·Registered Jan 07, 2014 – Dec 07, 2016CancelledRegistration details
- Analysis ID
- b211fd5c8be441579b909748183795a4
Company information
- Manufacturer
- Longteng Biotechnology Co., Ltd
- Manufacturer Country
- Taiwan, Province of China
- Authorized Representative
- Qizhe Biotechnology Co., Ltd
Product details
- Intended Use
- Qualitative detection of Troponin I antibodies in human serum.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1215 Creatine phosphokinase/creatine kinase or isoenzyme testing system
- Import Information
- Domestic;; Contract manufacturing
Dates and status
- Registration Date
- Jan 07, 2014
- Expiry Date
- Dec 07, 2016
- Cancellation Date
- Apr 25, 2018
Cancellation information
- Status
- Logged out
- Reason
- 自行鍵入
About this record
Access comprehensive regulatory information for Qizhe cardiomyogen in vitro reagent group in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number b211fd5c8be441579b909748183795a4 and manufactured by Longteng Biotechnology Co., Ltd. The authorized representative in Taiwan is Qizhe Biotechnology Co., Ltd.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices